Submit a manuscript Sign up for article alerts Contact us Support

About Hereditary Cancer in Clinical Practice

This page includes information about the aims and scope of Hereditary Cancer in Clinical Practice, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.

Aims & scope

Hereditary Cancer in Clinical Practice is an open access journal that publishes articles of interest for the cancer genetics community and serves as a discussion forum for the development of appropriate healthcare strategies.

Cancer genetics encompasses a wide variety of disciplines and knowledge in the field is rapidly growing, especially as the amount of information linking genetic differences to inherited cancer predispositions continues expanding. With the increased knowledge of genetic variability and how this relates to cancer risk there is a growing demand not only to disseminate this information into clinical practice but also to enable competent debate concerning how such information is managed and what it implies for patient care.

Hereditary Cancer in Clinical Practice is an established journal published since 2003. This publication is partly financed by the Polish Ministry of Science and Higher Education.

The list of topics includes but is not limited to:

  • Original research articles on any aspect of inherited predispositions to cancer.
  • Reviews of inherited cancer predispositions.
  • Application of molecular and cytogenetic analysis to clinical decision making.
  • Clinical aspects of the management of hereditary cancers.
  • Genetic counselling issues associated with cancer genetics.
  • The role of registries in improving health care of patients with an inherited predisposition to cancer.

Submission of gene variant data to genetic databases

Hereditary Cancer in Clinical Practice supports the recommendations of the Human Variome Project (Cotton RG et al. 2007.Nat Genet. 39: 433). Consequently, authors are required to submit all detected variants/mutations included in their article to the respective public Locus Specific Database (LSDB) or other public resource (such as dbSNP) prior to acceptance. Authors must confirm the status of database submission in their cover letter.

Open access

All articles published by Hereditary Cancer in Clinical Practice are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.

Authors of articles published in Hereditary Cancer in Clinical Practice are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.

For authors who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.

Article-processing charges

Open access publishing is not without costs. Hereditary Cancer in Clinical Practice therefore levies an article-processing charge of £1325/$2215/€1600 for each article accepted for publication. We routinely waive charges for authors from low-income countries. Generally, if the submitting author's institution is a Member the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. For further details, see our article-processing charge page. A limited number of waivers for article-processing charges are also available at the editors' discretion, and authors wishing to apply for these waivers should contact the editors.

Indexing services

All articles published in Hereditary Cancer in Clinical Practice are included in PubMed, the most widely used biomedical bibliographic database service, which is run by the US National Library of Medicine. Other bibliographic databases that index articles published in Hereditary Cancer in Clinical Practice include:

  • CABS
  • CAS
  • Cases Database
  • Citebase
  • DOAJ
  • Embase
  • EmBiology
  • Google Scholar
  • Index Copernicus
  • OAIster
  • PubMed
  • PubMed Central
  • Science Citation Index Expanded
  • SCImago
  • Scirus
  • Scopus
  • SOCOLAR
  • Zetoc

The full text of all research articles is deposited in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and other digital archives including e-Depot (The Netherlands).

The full text of all research articles published by BioMed Central is also available on SpringerLink.

All case reports published in this journal will also be indexed in Cases Database.

Hereditary Cancer in Clinical Practice is tracked by Thomson Reuters (ISI) and has an Impact Factor of 1.71.

Publication and peer review process

Criteria for publication

 

Hereditary Cancer in Clinical Practice considers the following types of articles:

Research: reports of data from original research.

Reviews: comprehensive, authoritative, descriptions of any subject within the journal’s scope. These are usually written by opinion leaders invited by the Editorial Board.

Case reports: reports of clinical cases that can be educational, describe a diagnostic or therapeutic dilemma, suggest an association, or present an important adverse reaction. All case report articles should indicate that informed consent to publish the information was granted from the patients or their guardians.

Commentaries: short, focused and opinionated articles on any subject within the journal’s scope, which are usually related to a contemporary issue and may be commissioned from opinion leaders in the field.

Debate articles: presentations of an argument that is not essentially based on practical research. Debate articles can report on all aspects of the subject including sociological, philosophical and ethical aspects.

Letter to the Editor: these can take three forms: a substantial re-analysis of a previously published article, or a substantial response to such a re-analysis from the authors of the original publication, or an article that may not cover 'standard research' but that may be relevant to readers.

Peer-review policies

Manuscripts are screened for general suitability before being assigned to at least two peer reviewers. Hereditary Cancer in Clinical Practice operates an 'open' peer-review system. Reviewers' names are included on the peer review reports, and reports are made publicly available. The Editors-in-Chief are responsible for the final decision on acceptance or rejection of a manuscript.

Edited by Jan Lubinski, Rodney J. Scott and Rolf Sijmons, Hereditary Cancer in Clinical Practice is supported by an expert Editorial Board.

Hereditary Cancer in Clinical Practice operates an 'open peer review' policy meaning reviewers are asked to sign their reviews. The pre-publication history including all submitted versions, reviewers' reports and authors' responses will be linked to from the published article.

Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My Hereditary Cancer in Clinical Practice, a personalized section of the site.

Reprints

High-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.

Supplements

Hereditary Cancer in Clinical Practice will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.

Editorial policies

All manuscripts submitted to Hereditary Cancer in Clinical Practice should adhere to BioMed Central's editorial policies.

Citing articles in Hereditary Cancer in Clinical Practice

Articles in Hereditary Cancer in Clinical Practice should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.

Article citations follow this format:

Authors: Title. Hered Cancer Clin Pract [year], [volume number]:[article number].

e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Hered Cancer Clin Pract 2009, 1:115.

refers to article 115 from Volume 1 of the journal.

Why publish your article in Hereditary Cancer in Clinical Practice?

High visibility

Hereditary Cancer in Clinical Practice's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.

Speed of publication

Hereditary Cancer in Clinical Practice offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF; the article will then be available through Hereditary Cancer in Clinical Practice, BioMed Central and PubMed Central and will also be included in PubMed.

Flexibility

Online publication in Hereditary Cancer in Clinical Practice gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).

Promotion and press coverage

Articles published in Hereditary Cancer in Clinical Practice are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Hereditary Cancer in Clinical Practice's pages and on the BioMed Central homepage.

In addition, articles published in Hereditary Cancer in Clinical Practice may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Hereditary Cancer in Clinical Practice. A list of articles recently press-released by journals published by BioMed Central is available here.

Authors of articles published in Hereditary Cancer in Clinical Practice retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright and license agreement).

For further information about the advantages of publishing in a journal from BioMed Central, please click here.